Vascular endothelial-specific cadherin (VE-cadherin) is an endothelial cell-specific adhesion molecule, localized at cell-cell contact sites. It is involved in physiological and pathological angiogenesis. In this study, we showed that in vitro a soluble N-terminal fragment of VE-cadherin (EC1-3) corresponding to cadherin 1-3 ectodomains inhibited vascular endothelial growth factor-stimulated endothelial cell proliferation and capillary tube structure formation in the matrigel model. In vivo, EC1-3 was tested in a murine colon cancer model. EC1-3-expressing colon cancer C51 cells were subcutaneously grafted into nude mice, and tumor growth and angiogenesis were evaluated. At day 33, the mean volume of the tumors developed was reduced (510 ± 104 versus 990 ± 120 mm 3 for control). Similarly, injection of EC1-3 virus-producing cells into established C51 tumors resulted in an inhibition by 33% of tumor growth. Immunohistological staining of vessels on tumor sections showed a significantly reduced intratumoral angiogenesis. Furthermore, EC1-3 did not induce vessel injury in the lung, liver, spleen, heart and brain in the mice. These results suggest that the soluble N-terminal fragment of VE-cadherin EC1-3 could exert an antitumoral effect by targeting tumor angiogenesis, which included blocking endothelial cell proliferation and capillary tube formation with no obvious toxicity on normal organs.
Introduction
Vascular endothelial-specific cadherin (VE-cadherin or cadherin-5) is an endothelial cell-specific adhesion molecule, localized at cell-cell contact sites, that mediates vascular cell to cell interaction. 1 VE-cadherin has a crucial function in various aspects of vascular biological functions, including endothelial cell migration, 2 survival, 3 contact-induced growth inhibition and vascular integrity. [4] [5] [6] Monoclonal antibodies directed against VE-cadherin ectodomains has been shown to be able to inhibit VE-cadherin association, block angiogenesis and induce endothelial cell apoptosis in vitro. 7 Previous investigations also showed that a VE-cadherin null mutation resulted in embryonic lethality at 9.5-10 days of development accompanied by impaired angiogenesis. 3, 8 Deficiency or cytosolic truncation of VE-cadherin induced endothelial cell apoptosis and abolished the transmission of the endothelial cell survival signal by vascular endothelial growth factor (VEGF). 3 VE-cadherin is a transmembrane glycoprotein with a typical modular structure comprising an N-terminal ectoplasmic domain composed of five homologous cadherin domains (EC1-5), a single hydrophobic membrane-spanning region, and a C-terminal cytoplasmic domain. 2, 9 Murine VE-cadherin presented 75% identity (90%, considering conservative amino-acid substitutions) with the human homolog. 10, 11 The cytoplasmic tail of VE-cadherin forms complexes with cytoplasmic components (b-catenin, plakoglobin, p120 and a-catenin) to ensure complex attachment to the actin filament network on the cytoskeleton. Dissociation of the catenins from this complex disturbed the stability of cell-cell adhesion. 12, 13 VE-cadherin extracellular part interacts homophilically with an identical molecule present on an adjacent cell.
VE-cadherin association with the cytoskeleton is not required for its localization at cell-cell contact sites during the early steps of endothelial cell junction organization, suggesting that the extracellular domain of the molecule is responsible for initial homotypic recognition. 3, 5, 11 This explains that a truncated VE-cadherin, lacking the cytoplasmic domain, could localize at cell-cell contact sites. 14 The function of VEGF/VEGF receptor may be controlled by VE-cadherin-mediated cell confluence, because in confluent endothelial cells, VEGFR-2 is dislocated and forms a complex with VE-cadherin, leading to the inhibition of its tyrosine phosphorylation and consequently in the attenuation of mitogen-activated protein kinase activation. 3, 15, 16 Junctional phosphatases such as DEP-1/CD148 were shown to inactivate VEFGR-2 within the complex and VE-cadherin-b-catenin complex may also participate in this process. In sparse cells or in VE-cadherin-null cells, this phenomenon cannot occur and the receptor is fully activated by the growth factor. 17 It has been shown that monoclonal antibody against extracellular part of VE-cadherin was able to disrupt endothelial junctions in growing vessels, in which endothelial cells are migrating and junctions are weak, without affecting stabilized junctions in normal vessels. 1, 18 These studies indicated that targeting the extracellular domain of VE-cadherin should be a good strategy for inhibiting angiogenesis without affecting endothelial cell vasculature.
Therefore, we constructed ReEC1-3, a retrovirus encoding a secreted form of the N-terminal fragment of VE-cadherin ectodomains EC1-3 and we evaluated the effect of secreted EC1-3 on angiogenesis including endothelial cell proliferation, capillary tube structure formation and its consequence on tumor proliferation in a mice model xenografted with colon cancer C51.
Materials and methods

Cell culture and animals
Human microvascular endothelial cell-1 (HMEC-1) cells were cultured in MCDB-131 medium supplemented with 10% fetal calf serum, and 0.1 ng ml À1 epidermal growth factor (EGF). 19 Calf pulmonary aortic endothelial (CPAE) and human umbilical venous endothelial cells (HUVECs) were cultured in modified Eagle's medium with 20 and 10% fetal calf serum, respectively as described. 20 The C51 murine colon cancer cell line was cultured in RPMI 1640 with 15% fetal calf serum. Dulbecco's modified Eagle's medium with 10% fetal calf serum was used to culture 293-EBNA cells (Invitrogen, Carlsbad, CA).
Nude mice, 5-6 weeks old on arrival, were obtained from IFFA-Credo (France). All animal studies were conducted in accordance with institutional guidelines for the care and use of experimental animals.
RNA isolation and reverse transcription-PCR
Total RNA was extracted from HMEC-1 cells by using the SV total RNA isolation system (Promega, Fitchburg, WI). Reverse transcription-PCR for the EC1-3 encoding gene (from positions 121-1248) of human VE-cadherin was performed on total RNA by using the Access RT-PCR system (Promega) according to manufacturer's instructions. The primers used were: 5 0 -ATGCAGAG GCTCATGATGCT-3 0 for the sense primer and 5 0 -CT GGTAGGGCTTGGCAAACT-3 0 for the antisense primer. Amplification was performed using a thermal cycler for 34 cycles under the following conditions: denature template for 30 s at 94 1C, annealing for 1 min at 60 1C and elongation for 1 min at 68 1C.
Construction of the ReEC1-3 retrovirus
The product of reverse transcription-PCR was used as the template for PCR. A BglII restriction site was introduced into the sense primer; a stop codon and an EcoRI site were introduced into the antisense primer. The fragment resulting from PCR was subcloned into the pIRES/green fluorescent protein (GFP) co-expressing vector. An 89-bp mouse urokinase signal peptide was inserted into the expression vector upstream of the EC1-3 gene. EC1-3-expressing plasmid (pEC1-3), the constructed retrovirus vector, was subsequently verified by sequence analysis. EC1-3 encoded the 375-amino-acid N-terminal fragment of VE-cadherin. To produce the recombinant retrovirus ReEC1-3, pEC1-3 was co-transfected with pVSV-G and pGAG-POL plasmids into the 293-EBNA packaging cell line by using 'lipofectamin plus' reagent (Invitrogen). Another recombinant retrovirus Re(His) 6 EC1-3, which expresses N-terminal-(His) 6 -taged EC1-3, was obtained by PCR to introduce the tag sequence 5 0 -CATCACCATCACCATCAC-3 0 into pEC1-3 between secretion signal sequence and EC1-3 sequence. Control recombinant virus ReGFP was prepared by co-transfection of pIRES/GFP with pVSV-G and pGAG-POL plasmids.
Cell transformation HMEC-1, CPAE and HUVEC exponentially growing endothelial cells or cell lines were infected with the retrovirus. The transformed cell line HMEC-EC1-3 was isolated on the basis of GFP expression using a fluorescence cell sorter. The HMEC-GFP control cell line was also obtained for subsequent analysis. C51GFP, C51EC1-3 and C51(His) 6 EC1-3, murine colon cancer cell lines were obtained in the same manner through infection of C51 cells.
Western blot analysis Parent HMEC-1 or transformed HMEC-GFP and HMEC-EC1-3 cell supernatants were prepared for western blot for detection of EC1-3 secretion.
Samples were run on a 7.5% SDS-polyacrylamide gel in a nonreduced condition and transferred to a nitrocellulose membrane (Schleicher & Schuell, Keene, NH). After 2 h incubation in blocking buffer (5% nonfat dry milk, 0.05% tween-20 in TBS), the membrane was incubated with Cad-5 anti-human VE-cadherin monoclonal antibody at room temperature for 2 h. After three washes with TBS-0.05% tween-20, the membrane was incubated with a peroxydase-conjugated rabbit anti-mouse serum (Interchim, Montluc¸on, France) at room temperature for 1 h. The result was visualized using an ECL system (Amersham, Buckinghamshire, UK).
Proliferation assay
Transformed or parent endothelial cells were plated at 5 Â 10 4 cells ml À1 in 24-well plates and incubated in normal culture medium or EC1-3-rich conditioned medium collected from C51 parent cell, C51GFP-transformed cell and C51EC1-3-transformed cell cultures. The cell proliferation assay was performed with or without VEGF stimulation at 100 ng ml À1 (R&D System, Abingdon, UK). The cell proliferation rate was evaluated by counting cell numbers at 72 h after inoculation. Each test was performed in triplicate and the results were obtained in three separate experiments.
Capillary tube formation assay Each well in a 24-well plate was coated with 200 ml of matrigel (Becton-Dickinson, Franklin Lakes, NJ) 2 h before use. Endothelial cells were seeded at 1 Â 10 5 per well and incubated for 24 h in normal culture media. The capillary tube structure was observed and photographed under a fluorescent microscope.
In vivo tumor growth after injection of EC1-3 gene transduced tumor cells
To observe the tumor growth of EC1-3 gene transferred C51 cells, transformed C51EC1-3 cells, C51GFP control cells or the C51 parent cells were injected in the dorsa of nude female mice (7-8 weeks old) at 2 Â 10 6 cells per animal. Each group contained eight animals (Janvier, France). Tumor development and growth were evaluated over 30 days by measuring the two diameters, and the tumor volume was calculated as follows: length Â (width) 2 Â p/6.
In vivo intratumoral injection of virus-producing cells
Then we performed the in vivo intratumoral gene transfer experiments by injecting 293-EBNA virus-producing packaging cells. Briefly, cultured C51 parental cells were harvested, washed and resuspended in phosphate-buffered saline at 2 Â 10 7 cells ml À1 , and a volume of 100 ml containing 2 Â 10 6 cells was injected subcutaneously into the dorsa of 7-week-old nude female mice. When the tumors became palpable with a diameter of 5-6 mm, the mice were divided randomly into four experimental groups, and each group contained seven mice. At days 8 and 12, the mice in the different groups received two injections within and around the tumors of either irradiated 3 Â 10 6 293-EBNA cells, 293 ReGFP-producing cells, 293 ReEC1-3-producing cells or phosphatebuffered saline, respectively. The tumor volume was measured and calculated.
Immunohistological staining of vessels Mice were killed 30 days after tumor implantation. Immunostaining of vessels and angio-index evaluation were performed as previously described. 19, 20 Tumors were fixed overnight in 100% absolute ethyl alcohol and embedded in paraffin. Tumor sections (5-m thick) were then prepared. For vessel staining, tumor sections were incubated for 1 h with a rat antibody directed against mouse CD31 (Pharmingen, France) and then with a biotinylated goat anti-rat immunoglobulin-G antibody for 15 min. After washing, sections were incubated with streptavidin-peroxidase and vessels were visualized by staining in a peroxidase substrate, diaminobenzidin. Meyer's hematoxylin was used for counterstaining. The level of vascularization was evaluated as previously described by Weidner et al. 21 and the angio-index presented is the mean number of microvessels per microscopic field ( Â 200).
Electrotransfer of EC1-3-expressing plasmid and observation of vessel permeability pEC1-3, the EC1-3-expressing plasmid was prepared by using the Endofree DNA maxiprep kit (Qiagen, Venlo, Netherland) and suspended in physiological saline. After anesthesia, 7-to 8-week-old female nude mice received an injection of 15 mg of plasmid DNA in each leg in the tibial/cranial muscle tissue after stimulation with eight transcutaneous electrical pulses every 20 ms at 170 V cm
À1
. The pIRES/GFP control plasmid was injected and electrotransfered into the muscles of the mice in the control group as described. 22 Each group contained eight mice. Three and 5 days after the electrotransfer, mice were killed, and lung, liver, brain, spleen, and heart tissues were removed, fixed and submitted to histological analysis to determine whether hemorrhage had occurred.
Statistical analysis
The Mann-Whitney method was used for the statistical analysis for both in vivo and in vitro experiments. A P-value of o0.05 was considered to be significant.
Results
EC1-3 inhibited proliferation of endothelial cells
To evaluate the antiangiogenic effect of transgene product EC1-3, HMEC-1, HUVEC and CPAE cells were infected with ReEC1-3, the virus expressing EC1-3 or with a ReGFP control virus. After culture in selective medium, we obtained the transformed cell lines. The secretion of EC1-3 in culture media was confirmed by western blot and the Figure 1 shows the result of HMEC-1 cell lines.
To test the effect of EC1-3, we examined the endothelial cell proliferation either after direct ReEC1-3 viral infection or after the addition of the conditioned medium rich in EC1-3. ReEC1-3-infected HMEC-1 cells showed a blockage of proliferation (about 60% under the stimulation of VEGF and about 50% without VEGF) (Figure 2a ). HUVEC and CPAE cells appeared more sensible, because we observed the pronounced apoptosis in these cells at 72 h after ReEC1-3 viral infection. These cells changed morphologically exhibiting membrane blebbing, cell rounding, and formed floating aggregates. The same morphological changes did not occur with the endothelial cells infected with control virus. Then, we examined the effects of secreted EC1-3 in the culture 
EC1-3 inhibited capillary tube formation of endothelial cells in vitro
To further explore the antiangiogenic mechanisms of EC1-3, we compared the ability to form capillary-like tubes of HMEC-EC1-3 cells, HMEC-GFP cells and the HMEC-1 parent cells. As shown in Figure 3 , after 24 h incubation on matrigel, both control cells (HMEC-GFP cells and the HMEC-1 parent cells) formed an intense cellular network, whereas the EC1-3-expressing cells failed to construct a similar structure. After 48 h of incubation on matrigel, HMEC-EC1-3 cells only formed a discontinuous intercellular-connection structure, while both control cells have well-established capillary-like tubes.
EC1-3 inhibited intratumor angiogenesis and tumor growth in mice
We then evaluated the effect of EC1-3 on tumor growth in vivo. EC1-3-transformed mouse colon cancer cells (C51EC1-3), C51GFP control cells as well as C51 parent cells were grafted into the dorsa of the nude mice. Tumor growth was monitored over 33 days. At the end of the experiment, tumor growth in the C51EC1-3 group showed an inhibition by 49% as compared with the control groups. The tumors in the C51EC1-3 group reached a mean volume of 510 ± 104 mm 3 , whereas the tumor volumes grew much faster with volumes of 991±120 mm 3 in C51GFP group and 989±108 mm 3 in C51 parental control group (Figure 4a) . The experiments with the intratumoral injection of the virus-producing cells revealed that C51 tumor growth was significantly inhibited by about 33% (Po0.05) after the injection of ReEC1-3 virus-producing 293 cells (Figure 4b ). Then these mice were killed and the vessel density was analyzed within the tumors. Using the procedure as described by Weidner et al., 21 the vessel numbers in the tumor were counted after immunohistological staining with the specific antibody against endothelial cells (anti-platelet endothelial cell adhesion molecule-1), and the mean vessel numbers were calculated as angio-index. The result showed a very significant reduction of the number of vessels in C51EC1-3 tumors (22.5±5.1) comparing with 65 ± 9.5 in the C51GFP group, and 58.3 ± 7.7 in the C51 parental cell group. Figure 5 shows the intratumoral vascularization in these tumor sections. 
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An increase in permeability of normal vessels might occur when targeting VE-cadherin, as described the experiments with anti-VE-cadherin antibodies. 1, 7 We therefore analyzed the effect of EC1-3 on vessel permeability in vivo with a method of electrotransfer. The pEC1-3 plasmid encoding EC1-3 driven by the LTR retrovirus promoter has been injected into mouse skeleton muscle according to the established protocol. 22 The secretion of EC1-3 in blood plasma was confirmed by western blot, 3 and 5 days after the electrotransfer. Mice were killed at days 3 and 5, respectively, for histological examination. The analysis of the discontinuous sections of the lung, spleen, liver, brain and heart did not reveal visible sign of hemorrhage. Furthermore, no evident injury of important mouse organs was noticed during the period of the experiments, which lasted routinely 30 days. Therefore, EC1-3 secreted in plasma did not affect the integrity of vessels within these organs of the mice.
Discussion
There is substantial preclinical and clinical evidence that angiogenesis has an important function in the development of tumors and the progression of malignancies.
Inhibiting angiogenesis has been shown to suppress tumor growth and metastasis in many preclinical models. Numerous antiangiogenic molecules have therefore been investigated and have proven effective in preclinical and clinical investigation. These include vascular disrupting agents, or endothelial disrupting agents that attempt to destroy the vascular endothelium that supplies rapidly dividing neoplasms, and antiangiogenesis agents that inhibit endothelial cell survival, proliferation, migration and blood 'capillary-like tube formation used for the development of a new tumor blood supply. [23] [24] [25] Most of these are indirect inhibitors, either targeting angiogenic growth factors or blocking the signaling pathways activated by these growth factors. Although these compounds seem to represent an efficient strategy in cancer treatment, they possess an intrinsic threat to induce resistance. 26 Therefore, the finding of new antiangiogenic molecules remains as important in cancer therapy.
VE-cadherin, which mediates endothelial cell-cell adherent junctions, has an important role in capillary tube formation, the maintenance of permeability and contact-regulated cell proliferation. Antagonizing homophilic-type association between VE-cadherin molecules has been demonstrated to be an attractive antiangiogenic-based anticancer strategy. 1 It was reported 
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that monoclonal antibody, which is able to block VE-cadherin adhesive properties, was effective in reducing angiogenesis in different tumor models in the adult. 27 Therefore, we assumed that the soluble N-terminal fragment of VE-cadherin could block the homophilictype association of VE-cadherin and inhibit tumor angiogenesis.
We constructed ReEC1-3 retrovirus and established several cell lines bearing EC1-3 transgene and evaluated the antiangiogenic activity of the transgene in vitro and in vivo. The results showed that EC1-3-enriched conditioned media from C51EC1-3 cells significantly suppressed endothelial cell proliferation in vitro compared with that from the control cells. This inhibition was specific as the proliferation of several tumor cell lines, such as C51 and MDA-MB-231, were not affected by EC1-3 in their culture media (results not shown). 28 The direct infection of HUVEC and CPA endothelial cells with EC1-3 retrovirus appeared to induce rapid cell apoptosis of these cells, as they were unable to survive for more than 3 days; whereas, it was not the case when these cells were 
infected with the ReGFP control virus, indicating that the apoptosis was caused by transgene product, not virus infection.
These data are in agreement with the report demonstrating that EC1-3 might block the signal-transduction pathway of VEGF/VEGF receptors. [29] [30] [31] [32] [33] Indeed, the activation of the VEGF receptor by tyrosine phosphorylation was previously shown to be inhibited when cells were confluent. Doubtlessly, EC1-3 suppress endothelial cell proliferation by probably antagonizing cell-cell contacts through interaction with cell-surface VE-cadherin, thereby inducing the inhibition of contact-regulated proliferation.
Capillary tube formation is a critical step before the establishment of a continuous vessel lumen. It is known that both VE-cadherin and CD31 are implicated in the formation of the capillary tube structure, [34] [35] [36] [37] because the interaction of CD31 and VE-cadherin with b-catenin and subsequently with F-actin to form a functional complex controls endothelial cell tube formation. Accordingly, both monoclonal antibodies directed against CD31 or VE-cadherin prevented the formation of endothelial tubes. Consistent with this finding, we observed similarly that the capillary tube formation ability of EC1-3-expressing HMEC-1 was also diminished as compared with that of the control cells. In fact, only some aggregated cell masses were obtained with HMEC-EC1-3 cells at 24 h after inoculation in matrigel assay; whereas, HMEC-1 and HMEC-GFP cells were able to assemble an intact capillary tube structure. This inhibitory effect was more evident at 48 h. These data suggested the antiangiogenic activity of EC1-3 in neutralizing the function of VE-cadherin during the morphogenetic phase.
The antitumoral effect of EC1-3 was confirmed in the murine colon carcinoma model. The results of EC1-3 gene transduced C51 cells showed that the tumor growth of these cells was suppressed by about 49% in the C51-EC1-3 group as compared with that obtained in the C51GFP control group. To further approach the gene therapy practice, the ReEC1-3 virus-producing 293 cells were injected within and around the grafted C51 tumors in the mice. The injection resulted in a significant suppression by 33% of C51 tumor growth. Concomitantly, we observed that intratumoral vascularization was inhibited by over 60% as compared with that of control groups in the experiments with EC1-3-transfected C51 tumors. These data in vivo showed the antiangiogenic potential of EC1-3 in cancer treatment.
As VE-cadherin antibodies have been reported to increase normal vessel permeability, 1, 7, 14, 38 we extended our study on this particular effect of EC1-3 in the in vivo experiment. After the electrotransfer of EC1-3 gene into the muscles of the mice, we carefully examined these mice. In these treated mice, we did not observe evident increase in permeability of vessels in normal tissues as well as in the organs of lung, liver, brain, heart and spleen tissue. This indicates that EC1-3 may affect preferably growing vessels without causing massive disrupt of pre-existing endothelial monolayer, because of its specific activity of interrupting the homophilic-type association of individual endothelial cells. It seems to indicate that established VE-cadherin junctions within well-established blood vessels are stable so that they were not seriously affected.
Taken together, our results showed the antiangiogenic effects of EC1-3 in vitro and in vivo without noticeable modification of normal vessel integrity. The use of soluble fragment of VE-cadherin may be an alternative antiangiogenic strategy in cancer therapy.
